Ticker Details
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
IPO Date:	April 2, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$66.98B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.44 | 1.79%
Avg Daily Range (30 D):	$7.84 | 1.10%
Avg Daily Range (90 D):	$9.46 | 1.27%

Institutional Daily Volume
Avg Daily Volume:	.67M
Avg Daily Volume (30 D):	.7M
Avg Daily Volume (90 D):	.59M

Trade Size
Avg Trade Size (Sh.):	59
Avg Trade Size (Sh.) (30 D):	21
Avg Trade Size (Sh.) (90 D):	19

Institutional Trades
Total Institutional Trades:	11,775
Avg Institutional Trade:	$19.76M
Avg Institutional Trade (30 D):	$46.04M
Avg Institutional Trade (90 D):	$53.8M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$38.88M
Avg Closing Trade (30 D):	$96.67M
Avg Closing Trade (90 D):	$97.22M
Avg Closing Volume:	76.22K

News

May 21, 2026 @ 12:00 PM CytomX Therapeutics to Present at Upcoming June In... Source: Not Specified

May 18, 2026 @ 5:12 PM Nvidia Earnings Could Decide Whether the AI Trade ... Source: Itai Smidt

May 18, 2026 @ 5:00 PM Myasthenia Gravis Market Set to Surpass USD 16 Bil... Source: Delveinsight

May 18, 2026 @ 11:00 AM Regeneron Announces Strategic Collaboration with P... Source: Na

May 18, 2026 @ 10:28 AM Why Is Regeneron Stock Sinking Monday? Source: Vandana Singh

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$42.56	$6.99	$8.24
Diluted EPS	$41.05	$6.75	$7.87
Revenue	$14.92B	$3.61B	$3.88B
Gross Profit
Net Income / Loss	$4.42B	$727.2M	$844.6M
Operating Income / Loss	$3.63B	$642.9M	$879.9M
Cost of Revenue
Net Cash Flow	$-122.4M	$-153.1M	$610.6M
PE Ratio